Here is a list of medical research studies that we have completed over the years:
1.- A Phase III, randomized, double-blind, placebo-controlled study
To investigate the efficacy and safety of the Xaracoll Bupivicaine implant
(300mg Bupivicaine Hydrochloride) After open laparotomy Hernioplasty.
Completed: June 2016
2.- A randomized, double-blind, multicenter, superiority, placebo-controlled, phase 3 study of Pexiganan Cream 0.8% Applied twice daily for 14 days in the treatment
Of Adults with Mild infections of Diabetic Foot Ulcers.
Completed: August 2016
3.- A Phase 3, randomized, double-blind study comparing ABT-494 once
Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX- Naïve
Subjects with moderately to severely active rheumatoid arthritis.
Completed: October 2017
4.- A phase 3, randomized, double-blind study comparing ABT-494 to
Placebo and to Adalimumab in Subjects with Moderately to Severely
Active Rheumatoid Arthritis who are on a stable background of
Methotrexate (MTX) and who have an inadequate response to MTX
5.- A Multicenter, randomized, double-blind, crossover study to assess the
Injection Site Pain Associated with a Modified Etanercept Formulation in
Adult subjects with either Rheumatoid Arthritis or Psoriatic Arthritis.
Completed: November 2017
6.- A randomized, double-blind, double-dummy, Multicenter, Active-controlled study
To evaluate the efficacy and safety of Vedolizumab IV Compared to Adalimumab SC
In subjects with ulcerative Colitis.
Completed: January 2018
7.- Randomized, Double-blind, Multicenter, 3-Stage, Efficacy and Safety
Study of NI-071 and US Licensed Remicade® (Infliximab) for the treatment
Of patients with Rheumatoid Arthritis.
Sponsor: Nichi-Iko Pharmaceuticals
Completed: March 2018
8.- A phase III, double-blind, randomized, long-term, placebo-controlled,
Multicenter, study evaluating the safety and efficacy of Obeticholic Acid
In subjects with non-alcoholic steatohepatitis.
Completed: July 2018
9.- A phase III, randomized, open-label, comparative safety and efficacy
Trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in
Subjects with iron deficiency anemia and non-dialysis-dependent
Chronic kidney disease.
Completed: September 2018
10.- A randomized, double-blind, placebo-controlled, parallel group
Study of Patiromer for the enablement of SpironolactoneUse for Blood
Pressure Control in Patients with Resistant HypertensionAnd Chronic Kidney
Disease: Evaluation of Safety and Efficacy (AMBER)
Completed: March 2019
11.- A randomized parallel-group, placebo-controlled, double-blind,
multi-center trial to evaluate the efficacy and safety of the oral
sGC stimulator vericiguat to improve physical functioning in
activities of daily living in patients with heart failure and preserved
ejection fraction (VITALITY-HFpEF).
Completed: April 2019
12.- Evaluation of the Performance of the Clinical Genomics Colvera
Test in the Detention of Disease recurrence in Patients Diagnosed
With Colorectal Cancer.-NOVA
Sponsor: Clinical Genomics
Completed: August 2019
13.- A randomized, controlled double-blind study comparing the efficacy
And safety of Orelvo (voclosporin) (23.7mg twice daily) With Placebo
In Achieving Renal response in subjects with Active Lupus Nephritis
Sponsor: Aurinia Pharmaceuticals
Completed: January 2020
14.- Phase III, double-blind, randomized, placebo controlled, multicenter, and study
To assess the safety and efficacy of vm202 to treat chronic nonhealing foot
Ulcers in diabetic patients with concomitant peripheral arterial disease (PAD)
Sponsor: VM Biopharma
Completed: January 2020
El Paso Medical Research Institute is property of MEDRESEARCH, INC.
Enrolled Patients Will Be Compensated